BJP Try Advances in Psychiatric Treatment Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bushe, C.
Right arrow Articles by Leonard, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bushe, C.
Right arrow Articles by Leonard, B.
The British Journal of Psychiatry (2004) 184: s87-S93
© 2004 The Royal College of Psychiatrists

Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data

Chris Bushe, MB BS

Eli Lilly & Co. Ltd, Basingstoke, UK

Brian Leonard, PhD DSc MRIA

Pharmacology Department, National University of Ireland, Galway, Ireland

Correspondence: Dr Chris Bushe, Eli Lilly & Co. Ltd, Lilly House, Priestley Road, Basingstoke RG24 9NL,UK. Tel: (0)1256 775971; fax: (0)1256 775534; e-mail: bushe_chris{at}lilly.com

Declaration of interest C.B. is employed by Eli Lilly & Co. Ltd. B.L. has been consultantto Eli Lilly & Co. in regard to diabetes and schizophrenia.

Background Most evidence suggesting an association between schizophrenia, antipsychotic medications and diabetes has been based on retrospective studies not controlled for important confounders.

Aims To compare diabetogenic risk between antipsychotic medications; and to describe the limitations of current prospective data-sets.

Method Systematic review of prospective clinical data.

Results No difference in the incidence of glycaemic abnormalities between placebo cohorts and antipsychotic medication cohorts was identified. No significant difference between any of the antipsychotic medications studied in terms of their association with glycaemic abnormalities was identified. Treatment-related weight gain did not appear to increase the riskof developing diabetes.

Conclusions Diabetogenic potential ascribed to atypical antipsychotic drugs, resulting from retrospective studies, may be incorrect. Cohort sizes andincomplete sampling must preclude any definitive conclusions. Long-term, large, comparative prospective trials are needed, along with agreement upon glucose measurement of choice.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
P. Brook
Testing for diabetes
The British Journal of Psychiatry, January 1, 2005; 186(1): 78 - 79.
[Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
T. G. Dinan
Introduction
The British Journal of Psychiatry, April 1, 2004; 184(47): s53 - s54.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 2004 The Royal College of Psychiatrists.